DEA
RMD icon

DoubleLine ETF Adviser’s ResMed RMD Stock Holding History

DoubleLine ETF Adviser’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Sell
1,571
-211
-12% -$43.7K 0.13% 146
2026
Q1 		$400K Buy
+1,782
New +$444K 0.15% 130

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

DoubleLine ETF Adviser's RMD Position: Q2 2026 in Review

DoubleLine ETF Adviser reduced its ResMed (RMD) stake by 12% in Q2 2026, selling an estimated $43.7K and leaving 1,571 shares worth $306K. The position accounts for 0.13% of the portfolio, ranked #146.

DoubleLine ETF Adviser first reported a position in RMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $400K in Q1 2026. 887 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • DoubleLine ETF Adviser held 1,571 shares of ResMed worth $306K as of Q2 2026.
  • DoubleLine ETF Adviser sold 211 ResMed shares in Q2 2026, an estimated $43.7K.
  • ResMed made up 0.13% of DoubleLine ETF Adviser's portfolio in Q2 2026, its #146 holding.
  • DoubleLine ETF Adviser first reported a position in ResMed in Q1 2026 and has held it in 2 quarters since.
  • DoubleLine ETF Adviser's ResMed position peaked at $400K in Q1 2026.
  • 887 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on DoubleLine ETF Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.